These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17447314)

  • 1. Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
    TreatmentUpdate; 2007 Feb; 19(2):6-7. PubMed ID: 17447314
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. American study finds efavirenz linked to fat wasting.
    TreatmentUpdate; 2007 Feb; 19(2):4-6. PubMed ID: 17447313
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Efavirenz and fat wasting--what might be happening?
    TreatmentUpdate; 2007 Feb; 19(2):7-8. PubMed ID: 17447315
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 5. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 6. Complications and side effects. Minimizing fat loss--comparing nukes.
    TreatmentUpdate; 2007; 19(5):6. PubMed ID: 17955615
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus on fat.
    TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipodystrophy--nukes vs. protease inhibitors.
    TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute porphyria precipitated by efavirenz.
    Pavitt CW; Rampling T; Byrne R; Tyebally S; Reid T; Nelson M
    AIDS; 2015 May; 29(8):981-2. PubMed ID: 25909830
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.
    Martínez E; García-Viejo MA; Blanco JL; Bianchi L; Buira E; Conget I; Casamitjana R; Mallolas J; Gatell JM
    Clin Infect Dis; 2000 Nov; 31(5):1266-73. PubMed ID: 11073762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV agents. Using maraviroc in first-line therapy.
    TreatmentUpdate; 2007; 19(6):5-6. PubMed ID: 18041149
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.